42.75 USD
+0.12
0.28%
At close Apr 30, 4:00 PM EDT
After hours
42.75
+0.00
0.00%
1 day
0.28%
5 days
0.35%
1 month
6.48%
3 months
-3.95%
6 months
-1.61%
Year to date
-6.64%
1 year
-1.81%
5 years
-3.30%
10 years
63.04%
 

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Employees: 5,765

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $52.2M | Put options by funds: $35.2M

8% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 107

4% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 51

4% less capital invested

Capital invested by funds: $6.85B [Q3] → $6.58B (-$273M) [Q4]

2% less funds holding

Funds holding: 325 [Q3] → 319 (-6) [Q4]

2.02% less ownership

Funds ownership: 68.28% [Q3] → 66.27% (-2.02%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$43
1%
upside
Avg. target
$46
6%
upside
High target
$48
12%
upside

2 analyst ratings

positive
0%
neutral
100%
negative
0%
Baird
Catherine Schulte
5% 1-year accuracy
1 / 19 met price target
1%upside
$43
Neutral
Maintained
21 Apr 2025
UBS
John Sourbeer
0% 1-year accuracy
0 / 3 met price target
12%upside
$48
Neutral
Maintained
7 Feb 2025

Financial journalist opinion

Based on 9 articles about QGEN published over the past 30 days

Positive
Zacks Investment Research
16 hours ago
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Neutral
Business Wire
1 day ago
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy. This expanded offering supports standardized, high-precision quality contr.
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
Positive
Zacks Investment Research
1 day ago
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Neutral
Business Wire
1 week ago
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These new developments will be showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30 in Chicago. Important updates include a new set of QIAseq panels for comprehensive genomic profiling (CGP) and a new QIAcuity digital PCR (dPCR).
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
Positive
Zacks Investment Research
2 weeks ago
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Neutral
Business Wire
2 weeks ago
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation. These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide and address different customer segments: QIAsymphony Connect, which marks the next generation of the flagship QIAsym.
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
Neutral
Business Wire
3 weeks ago
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect.
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Neutral
Business Wire
3 weeks ago
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued.
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
Neutral
Business Wire
4 weeks ago
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep&amp Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This new solution combines sample preparation and quantitative PCR (qPCR) into a single workflow, providing a rapid and accessible tool for detecting malaria-causing parasites from blood samples. Malaria remains one of the world's most pressing public health cha.
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
Neutral
Business Wire
1 month ago
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2024 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 20.
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
Charts implemented using Lightweight Charts™